Rapport Therapeutics (RAPP)
Rapport Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.1M
Short interest
settlement 2026-10-15
11.8
Days to cover
+6.9 days vs prior
61.7%
Short share of volume
2026-11-02
29
Fails to deliver
settlement 2026-09-18
Tue 9 Mar
Next earnings
estimated date
7 people
Insiders buying, 30 days
$22.0M combined, latest 2026-10-28
$15.1M
Insider flow, 90 days
11 buys, 20 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in RAPP is 3,051,500 shares, up 803,431 shares over the last month. Over the last 48 readings it ranged from 1,499,086 shares (15 January 2025) to 3,849,519 shares (31 March 2026). At the reported average volume of 260K shares a day that is 11.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rapp" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,051,500 | -4.5% | 259,510 | 11.76 |
| 2026-09-30 | 3,194,008 | +42.1% | 660,098 | 4.84 |
| 2026-09-15 | 2,248,069 | +0.6% | 284,289 | 7.91 |
| 2026-08-31 | 2,233,723 | +0.4% | 271,423 | 8.23 |
| 2026-08-14 | 2,225,618 | -1.0% | 295,758 | 7.53 |
| 2026-07-31 | 2,248,235 | -16.4% | 299,167 | 7.51 |
| 2026-07-15 | 2,690,734 | +19.1% | 438,999 | 6.13 |
| 2026-06-30 | 2,260,158 | +0.6% | 488,981 | 4.62 |
| 2026-06-15 | 2,246,097 | -8.7% | 316,690 | 7.09 |
| 2026-05-29 | 2,459,901 | +1.8% | 284,811 | 8.64 |
| 2026-05-15 | 2,417,349 | -20.7% | 348,797 | 6.93 |
| 2026-04-30 | 3,048,448 | -10.6% | 420,825 | 7.24 |
| 2026-04-15 | 3,409,588 | -11.4% | 240,545 | 14.17 |
| 2026-03-31 | 3,849,519 | +3.7% | 316,962 | 12.15 |
| 2026-03-13 | 3,711,232 | +5.6% | 407,399 | 9.11 |
| 2026-02-27 | 3,513,015 | +3.3% | 282,637 | 12.43 |
| 2026-02-13 | 3,402,222 | +3.4% | 255,102 | 13.34 |
| 2026-01-30 | 3,289,758 | +14.6% | 373,284 | 8.81 |
| 2026-01-15 | 2,870,977 | +6.6% | 360,318 | 7.97 |
| 2025-12-31 | 2,692,137 | +20.7% | 469,814 | 5.73 |
| 2025-12-15 | 2,230,607 | +3.8% | 337,978 | 6.60 |
| 2025-11-28 | 2,149,458 | +7.3% | 395,394 | 5.44 |
| 2025-11-14 | 2,002,709 | +3.6% | 380,210 | 5.27 |
| 2025-10-31 | 1,932,558 | -4.2% | 362,415 | 5.33 |
| 2025-10-15 | 2,016,786 | -33.5% | 429,698 | 4.69 |
| 2025-09-30 | 3,030,832 | -4.0% | 811,988 | 3.73 |
| 2025-09-15 | 3,158,524 | +0.4% | 2,698,088 | 1.17 |
| 2025-08-29 | 3,146,776 | +4.1% | 221,961 | 14.18 |
| 2025-08-15 | 3,023,076 | -0.9% | 163,332 | 18.51 |
| 2025-07-31 | 3,051,967 | +6.7% | 159,326 | 19.16 |
| 2025-07-15 | 2,860,712 | +1.1% | 169,334 | 16.89 |
| 2025-06-30 | 2,828,863 | -0.2% | 145,581 | 19.43 |
| 2025-06-13 | 2,833,255 | +8.0% | 267,254 | 10.60 |
| 2025-05-30 | 2,623,331 | +6.3% | 202,443 | 12.96 |
| 2025-05-15 | 2,468,259 | -2.2% | 107,477 | 22.97 |
| 2025-04-30 | 2,523,770 | +3.5% | 131,703 | 19.16 |
| 2025-04-15 | 2,438,677 | -12.9% | 217,693 | 11.20 |
| 2025-03-31 | 2,801,327 | +21.1% | 322,536 | 8.69 |
| 2025-03-14 | 2,312,622 | +27.9% | 399,067 | 5.80 |
| 2025-02-28 | 1,808,501 | +8.8% | 221,470 | 8.17 |
| 2025-02-14 | 1,662,019 | +10.2% | 94,253 | 17.63 |
| 2025-01-31 | 1,507,672 | +0.6% | 88,163 | 17.10 |
| 2025-01-15 | 1,499,086 | -15.2% | 112,862 | 13.28 |
| 2024-12-31 | 1,767,615 | -2.3% | 125,922 | 14.04 |
| 2024-12-13 | 1,808,388 | +1.0% | 143,529 | 12.60 |
| 2024-11-29 | 1,790,608 | +3.0% | 108,400 | 16.52 |
| 2024-11-15 | 1,737,758 | -17.7% | 80,161 | 21.68 |
| 2024-10-31 | 2,111,005 | +10.0% | 93,876 | 22.49 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of RAPP volume is 61.7%, down 4.2 points over the last five sessions. Over the last 30 readings it ranged from 35.7% (23 October 2026) to 74.5% (14 October 2026). The latest reading is 4.8 points above the 30-session average of 56.9%, on 372K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 229K | 372K | 61.7% | 0 |
| 2026-10-30 | 156K | 311K | 50.2% | 0 |
| 2026-10-29 | 547K | 1.2M | 45.4% | 6,952 |
| 2026-10-28 | 1.5M | 2.8M | 54.0% | 46,265 |
| 2026-10-27 | 139K | 210K | 66.3% | 0 |
| 2026-10-26 | 326K | 495K | 65.9% | 0 |
| 2026-10-23 | 186K | 520K | 35.7% | 3,780 |
| 2026-10-22 | 330K | 690K | 47.8% | 22,080 |
| 2026-10-21 | 413K | 893K | 46.2% | 17,065 |
| 2026-10-20 | 1.8M | 2.7M | 66.1% | 1,733 |
| 2026-10-19 | 66K | 104K | 63.7% | 0 |
| 2026-10-16 | 104K | 140K | 74.1% | 0 |
| 2026-10-15 | 77K | 116K | 66.1% | 0 |
| 2026-10-14 | 84K | 112K | 74.5% | 0 |
| 2026-10-13 | 57K | 122K | 46.5% | 4,053 |
| 2026-10-12 | 22K | 40K | 55.9% | 0 |
| 2026-10-09 | 35K | 78K | 44.9% | 0 |
| 2026-10-08 | 46K | 84K | 54.8% | 1,659 |
| 2026-10-07 | 54K | 89K | 60.5% | 0 |
| 2026-10-06 | 45K | 73K | 61.8% | 0 |
| 2026-10-05 | 29K | 57K | 51.5% | 0 |
| 2026-10-02 | 66K | 103K | 64.4% | 12,290 |
| 2026-10-01 | 48K | 113K | 42.1% | 0 |
| 2026-09-30 | 72K | 169K | 42.7% | 0 |
| 2026-09-29 | 155K | 239K | 64.9% | 0 |
| 2026-09-28 | 81K | 163K | 49.8% | 2,150 |
| 2026-09-25 | 197K | 322K | 61.3% | 100 |
| 2026-09-24 | 215K | 369K | 58.2% | 5,648 |
| 2026-09-23 | 159K | 282K | 56.5% | 5,946 |
| 2026-09-22 | 339K | 471K | 72.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 18 September 2026, the fails-to-deliver balance in RAPP is 29 shares, down 865 shares over the last settlement date. Over the last 30 readings it ranged from 7 shares (23 March 2026) to 41,900 shares (22 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-18 | 29 | $41.95 | $1K |
| 2026-09-03 | 894 | $48.69 | $44K |
| 2026-08-28 | 325 | $50.83 | $17K |
| 2026-08-19 | 2,723 | $49.01 | $133K |
| 2026-08-07 | 2,124 | $46.35 | $98K |
| 2026-07-17 | 1,718 | $40.13 | $69K |
| 2026-06-26 | 36 | $38.91 | $1K |
| 2026-06-24 | 4,340 | $38.88 | $169K |
| 2026-05-29 | 6,571 | $39.49 | $259K |
| 2026-05-28 | 4,384 | $39.51 | $173K |
| 2026-05-27 | 4,378 | $39.71 | $174K |
| 2026-05-22 | 41,900 | $36.70 | $1.5M |
| 2026-05-20 | 1,047 | $34.37 | $36K |
| 2026-05-19 | 352 | $35.18 | $12K |
| 2026-05-18 | 200 | $37.07 | $7K |
| 2026-05-14 | 2,292 | $38.08 | $87K |
| 2026-05-12 | 57 | $38.43 | $2K |
| 2026-05-08 | 4,238 | $39.93 | $169K |
| 2026-05-07 | 806 | $37.06 | $30K |
| 2026-05-04 | 500 | $33.89 | $17K |
| 2026-04-22 | 16,400 | $36.95 | $606K |
| 2026-04-15 | 650 | $36.15 | $23K |
| 2026-04-08 | 58 | $33.49 | $2K |
| 2026-04-06 | 7,136 | $33.58 | $240K |
| 2026-04-02 | 282 | $31.67 | $9K |
| 2026-04-01 | 8,485 | $31.29 | $265K |
| 2026-03-31 | 2,256 | $27.69 | $62K |
| 2026-03-27 | 78 | $29.00 | $2K |
| 2026-03-25 | 352 | $28.25 | $10K |
| 2026-03-23 | 7 | $27.08 | $190 |
Insider trades
SEC Form 4, newest first. JSONOver the last 90 days RAPP insiders reported 11 open-market buys ($22.0M) against 20 sells ($6.9M), so the dollar flow leans toward buying. Latest filing: HEALY JAMES (Director) on 2026-10-28.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-28 | HEALY JAMES | Director | Buy | 7K | $21.00 | $146K | 25K |
| 2026-10-28 | HEALY JAMES | Director | Buy | 4K | $21.00 | $79K | 15K |
| 2026-10-28 | HEALY JAMES | Director | Buy | 6K | $21.00 | $134K | 18K |
| 2026-10-28 | HEALY JAMES | Director | Buy | 952K | $21.00 | $20.0M | 2.8M |
| 2026-10-23 | Sanchez Ramiro | Director | Buy | 4K | $27.35 | $98K | 4K |
| 2026-10-22 | MARAGANORE JOHN | Director | Buy | 1K | $26.92 | $32K | 9K |
| 2026-10-22 | MARAGANORE JOHN | Director | Buy | 8K | $26.38 | $217K | 8K |
| 2026-10-22 | PAUL STEVEN M | Director | Buy | 36K | $27.28 | $974K | 77K |
| 2026-10-22 | Young Wendy B. | Director | Buy | 4K | $26.39 | $100K | 13K |
| 2026-10-22 | Silva Paul M | Director | Buy | 4K | $27.07 | $100K | 4K |
| 2026-10-21 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $29.16 | $64K | 450K |
| 2026-10-21 | Ignelzi Troy A. | Chief Financial Officer | Buy | 6K | $26.10 | $144K | 16K |
| 2026-10-07 | Ceesay Abraham | Chief Executive Officer | Sell | 1K | $30.66 | $35K | 452K |
| 2026-10-06 | Ceesay Abraham | Chief Executive Officer | Sell | 3K | $32.03 | $108K | 453K |
| 2026-09-30 | Gault Cheryl | Chief Operating Officer | Sell | 2K | $33.76 | $70K | 140K |
| 2026-09-30 | Gault Cheryl | Chief Operating Officer | Sell | 8K | $33.04 | $262K | 142K |
| 2026-09-23 | Ceesay Abraham | Chief Executive Officer | Sell | 43 | $41.05 | $2K | 457K |
| 2026-09-23 | Ceesay Abraham | Chief Executive Officer | Sell | 215 | $39.86 | $9K | 457K |
| 2026-09-23 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $39.05 | $76K | 457K |
| 2026-09-08 | Ceesay Abraham | Chief Executive Officer | Sell | 1K | $46.01 | $49K | 459K |
| 2026-09-08 | Ceesay Abraham | Chief Executive Officer | Sell | 7K | $45.55 | $325K | 460K |
| 2026-08-25 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 16K | $51.06 | $827K | 196K |
| 2026-08-25 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 21K | $50.31 | $1.0M | 212K |
| 2026-08-25 | Ceesay Abraham | Chief Executive Officer | Sell | 19K | $49.57 | $938K | 467K |
| 2026-08-24 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 13K | $50.00 | $658K | 233K |
| 2026-08-19 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 404 | $49.90 | $20K | 246K |
| 2026-08-11 | Ceesay Abraham | Chief Executive Officer | Sell | 6K | $48.62 | $282K | 486K |
| 2026-08-11 | Ceesay Abraham | Chief Executive Officer | Sell | 20K | $48.04 | $937K | 492K |
| 2026-08-11 | Ceesay Abraham | Chief Executive Officer | Sell | 4K | $46.90 | $172K | 511K |
| 2026-08-10 | Ceesay Abraham | Chief Executive Officer | Sell | 8K | $46.75 | $391K | 515K |
| 2026-08-10 | Ceesay Abraham | Chief Executive Officer | Sell | 14K | $45.97 | $651K | 523K |
| 2026-07-27 | Ceesay Abraham | Chief Executive Officer | Sell | 7 | $42.73 | $299 | 538K |
| 2026-07-27 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $42.11 | $93K | 538K |
| 2026-07-14 | Ceesay Abraham | Chief Executive Officer | Sell | 3K | $40.57 | $111K | 540K |
| 2026-07-14 | Ceesay Abraham | Chief Executive Officer | Sell | 5K | $39.72 | $218K | 543K |
| 2026-06-30 | Gault Cheryl | Chief Operating Officer | Sell | 1K | $43.15 | $43K | 150K |
| 2026-06-30 | Gault Cheryl | Chief Operating Officer | Sell | 3K | $42.17 | $140K | 151K |
| 2026-06-30 | Gault Cheryl | Chief Operating Officer | Sell | 4K | $41.39 | $157K | 154K |
| 2026-06-30 | Gault Cheryl | Chief Operating Officer | Sell | 2K | $40.09 | $76K | 158K |
| 2026-06-29 | Ceesay Abraham | Chief Executive Officer | Sell | 876 | $40.34 | $35K | 548K |
| 2026-06-29 | Ceesay Abraham | Chief Executive Officer | Sell | 7K | $39.77 | $292K | 549K |
| 2026-05-26 | Third Rock Ventures V, L.P. | 10% owner | Sell | 19K | $40.05 | $744K | 6.3M |
| 2026-05-11 | Third Rock Ventures V, L.P. | 10% owner | Sell | 134K | $40.24 | $5.4M | 6.3M |
| 2026-05-08 | Third Rock Ventures VI, L.P. | TenPercentOwner | Sell | 5K | $40.31 | $202K | 6.4M |
| 2026-05-08 | Third Rock Ventures V, L.P. | 10% owner | Sell | 5K | $40.31 | $202K | 6.4M |
| 2026-05-07 | Third Rock Ventures VI, L.P. | TenPercentOwner | Sell | 271K | $40.12 | $10.9M | 6.4M |
| 2026-05-07 | Third Rock Ventures V, L.P. | 10% owner | Sell | 271K | $40.12 | $10.9M | 6.4M |
| 2026-04-17 | Third Rock Ventures VI, L.P. | TenPercentOwner | Sell | 426K | $40.32 | $17.2M | 6.7M |
| 2026-04-17 | Third Rock Ventures V, L.P. | 10% owner | Sell | 426K | $40.32 | $17.2M | 6.7M |
| 2026-04-17 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 20K | $39.99 | $809K | 246K |
| 2026-04-14 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 10K | $35.08 | $358K | 267K |
| 2026-04-13 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 9K | $34.97 | $321K | 277K |
| 2026-04-10 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 500 | $34.98 | $17K | 286K |
| 2026-04-08 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 360 | $34.90 | $13K | 287K |
| 2026-03-30 | Gault Cheryl | Chief Operating Officer | Sell | 3K | $28.55 | $81K | 160K |
| 2026-03-30 | Gault Cheryl | Chief Operating Officer | Sell | 7K | $28.04 | $201K | 163K |
| 2026-03-25 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 10K | $29.99 | $303K | 287K |
| 2026-03-05 | Gault Cheryl | Chief Operating Officer | Sell | 2K | $28.93 | $58K | 170K |
| 2026-02-19 | Bredt David | Chief Scientific Officer | Exercise or conversion | 6K | $1.80 | $11K | 393K |
| 2026-02-18 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $29.80 | $63K | 21K |
| 2026-02-18 | Ceesay Abraham | Chief Executive Officer | Sell | 3K | $29.04 | $87K | 23K |
| 2026-02-18 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $29.80 | $68K | 556K |
| 2026-02-18 | Ceesay Abraham | Chief Executive Officer | Sell | 4K | $29.05 | $103K | 559K |
| 2026-02-17 | Bredt David | Chief Scientific Officer | Sell | 2K | $29.59 | $65K | 387K |
| 2026-02-17 | Bredt David | Chief Scientific Officer | Sell | 5K | $28.95 | $156K | 389K |
| 2026-02-17 | Bredt David | Chief Scientific Officer | Sell | 900 | $28.02 | $25K | 395K |
| 2026-01-20 | Ceesay Abraham | Chief Executive Officer | Sell | 5K | $26.11 | $133K | 26K |
| 2026-01-20 | Ceesay Abraham | Chief Executive Officer | Sell | 6K | $26.12 | $152K | 562K |
| 2026-01-15 | Bredt David | Chief Scientific Officer | Sell | 200 | $27.40 | $5K | 396K |
| 2026-01-15 | Bredt David | Chief Scientific Officer | Sell | 8K | $26.83 | $223K | 396K |
| 2025-12-31 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 3K | $30.05 | $85K | 297K |
| 2025-12-31 | Yeleswaram Krishnaswamy | Chief Development Officer | Grant | 9K | price not stated in the filing | not stated | 300K |
| 2025-12-31 | Bredt David | Chief Scientific Officer | Grant | 18K | price not stated in the filing | not stated | 411K |
| 2025-12-31 | Bredt David | Chief Scientific Officer | Sell | 7K | $30.05 | $197K | 404K |
| 2025-12-17 | Ceesay Abraham | Chief Executive Officer | Sell | 515 | $31.04 | $16K | 31K |
| 2025-12-17 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $30.04 | $73K | 31K |
| 2025-12-17 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $28.84 | $62K | 34K |
| 2025-12-17 | Ceesay Abraham | Chief Executive Officer | Sell | 600 | $31.04 | $19K | 568K |
| 2025-12-17 | Ceesay Abraham | Chief Executive Officer | Sell | 3K | $30.04 | $84K | 569K |
| 2025-12-17 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $28.84 | $70K | 571K |
| 2025-12-15 | Bredt David | Chief Scientific Officer | Sell | 796 | $30.68 | $24K | 393K |
| 2025-12-15 | Bredt David | Chief Scientific Officer | Sell | 8K | $29.95 | $231K | 393K |
| 2025-11-26 | Gault Cheryl | Chief Operating Officer | Sell | 5K | $30.10 | $150K | 172K |
| 2025-11-26 | Gault Cheryl | Chief Operating Officer | Exercise or conversion | 5K | $1.80 | $9K | 177K |
| 2025-11-17 | Ceesay Abraham | Chief Executive Officer | Sell | 3K | $25.44 | $72K | 36K |
| 2025-11-17 | Ceesay Abraham | Chief Executive Officer | Sell | 2K | $24.91 | $56K | 39K |
| 2025-11-17 | Ceesay Abraham | Chief Executive Officer | Sell | 3K | $25.43 | $78K | 574K |
| 2025-11-17 | Ceesay Abraham | Chief Executive Officer | Sell | 3K | $24.92 | $69K | 577K |
| 2025-11-17 | Bredt David | Chief Scientific Officer | Sell | 5K | $25.39 | $136K | 401K |
| 2025-11-17 | Bredt David | Chief Scientific Officer | Sell | 3K | $24.84 | $78K | 406K |
| 2025-10-15 | Ceesay Abraham | Chief Executive Officer | Sell | 755 | $26.17 | $20K | 41K |
| 2025-10-15 | Ceesay Abraham | Chief Executive Officer | Sell | 4K | $25.75 | $111K | 42K |
| 2025-10-15 | Ceesay Abraham | Chief Executive Officer | Sell | 1K | $26.14 | $31K | 580K |
| 2025-10-15 | Ceesay Abraham | Chief Executive Officer | Sell | 5K | $25.72 | $120K | 581K |
| 2025-10-15 | Bredt David | Chief Scientific Officer | Sell | 1K | $26.16 | $28K | 410K |
| 2025-10-15 | Bredt David | Chief Scientific Officer | Sell | 7K | $25.73 | $191K | 411K |
| 2025-09-17 | Ceesay Abraham | Chief Executive Officer | Sell | 700 | $27.04 | $19K | 46K |
| 2025-09-17 | Ceesay Abraham | Chief Executive Officer | Sell | 35K | $26.30 | $918K | 47K |
| 2025-09-17 | Ceesay Abraham | Chief Executive Officer | Sell | 1K | $26.87 | $38K | 585K |
| 2025-09-17 | Ceesay Abraham | Chief Executive Officer | Sell | 39K | $26.30 | $1.0M | 587K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON25 Form 144 notices on file for RAPP worth $44.7M at the prices reported; 4 in the last 90 days worth $2.8M. Latest: CHERYL GAULT filed on 2026-09-30 to sell 10,000 shares ($330K) from 2026-09-30.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-30 | CHERYL GAULTOfficer | 10K | $330K | 0.021% | 2026-09-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-25 | KRISHNASWAMY YELESWARAMOfficer | 37K | $1.8M | 0.077% | 2026-08-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-24 | KRISHNASWAMY YELESWARAMOfficer | 11K | $553K | 0.024% | 2026-08-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-19 | KRISHNASWAMY YELESWARAMOfficer | 2K | $103K | 0.004% | 2026-08-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-30 | CHERYL GAULTOfficer | 10K | $404K | 0.021% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-27 | Third Rock Ventures V, L.P.10% Stockholder | 19K | $743K | 0.039% | 2026-05-26 | Raymond James & Associates |
| 2026-05-11 | Third Rock Ventures V, L.P.10% Stockholder | 134K | $5.4M | 0.279% | 2026-05-11 | Raymond James & Associates |
| 2026-05-08 | Third Rock Ventures V, L.P.10% Stockholder | 5K | $202K | 0.010% | 2026-05-08 | Raymond James & Associates |
| 2026-05-07 | Third Rock Ventures V, L.P.10% Stockholder | 271K | $10.9M | 0.568% | 2026-05-07 | Raymond James & Associates, Inc. |
| 2026-04-17 | Third Rock Ventures V, L.P.10% Stockholder | 426K | $17.2M | 0.891% | 2026-04-17 | Raymond James & Associates |
| 2026-04-17 | KRISHNASWAMY YELESWARAMOfficer | 20K | $800K | 0.042% | 2026-04-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-13 | KRISHNASWAMY YELESWARAMOfficer | 19K | $662K | 0.041% | 2026-04-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-10 | KRISHNASWAMY YELESWARAMOfficer | 500 | $17K | 0.001% | 2026-04-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-08 | KRISHNASWAMY YELESWARAMOfficer | 360 | $12K | 0.001% | 2026-04-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-30 | CHERYL GAULTOfficer | 10K | $278K | 0.021% | 2026-03-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-25 | KRISHNASWAMY YELESWARAMOfficer | 10K | $286K | 0.021% | 2026-03-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-05 | Gault CherylOfficer | 2K | $58K | 0.004% | 2026-03-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-15 | DAVID BREDTOfficer | 17K | $466K | 0.036% | 2026-01-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-02 | Krishnaswamy YeleswaramOfficer | 3K | $85K | 0.006% | 2026-01-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-02 | DAVID BREDTOfficer | 7K | $197K | 0.014% | 2026-01-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-17 | THE DOROTHY CEESAY IRREVOCABLE TRUSTDirector, Officer | 15K | $469K | 0.032% | 2025-12-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-17 | ABRAHAM CEESAYDirector, Officer | 17K | $538K | 0.037% | 2025-12-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-15 | DAVID BREDTOfficer | 26K | $634K | 0.070% | 2025-10-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-17 | ABRAHAM CEESAYDirector, Officer | 53K | $1.4M | 0.144% | 2025-09-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-17 | THE DOROTHY CEESAY IRREV TRUST U/ADTD 03/27/2024Director, Officer | 46K | $1.2M | 0.125% | 2025-09-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON7 holders report 5% or more of RAPP in their latest filing, all on Schedule 13G (passive). The largest reported stake is Third Rock Ventures V, L.P. at 13.1% of the class (6,280,525 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Third Rock Ventures V, L.P.partnership | 6.3M | 13.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Third Rock Ventures GP V, L.P.partnership | 6.3M | 13.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | TRV GP V, LLCother entity | 6.3M | 13.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Third Rock Ventures VI, L.P.partnership | 969K | 2.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Third Rock Ventures GP VI, L.P.partnership | 969K | 2.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | TRV GP VI, LLCother entity | 969K | 2.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Cormorant Asset Management, LPinvestment adviser, partnership | 2.7M | 5.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Bihua Chenparent holding company, individual | 2.7M | 5.6% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 1 | Capital International Investorsinvestment adviser | 2.9M | 6.1% | 2026-06-30 |
| 2026-01-21 | 13G | BlackRock, Inc.parent holding company | 2.4M | 5.0% | 2025-12-31 |
| 2025-10-22 | 13G/Ano. 1 | JOHNSON & JOHNSONcorporation | 1.8M | 4.9% | 2025-09-30 |
| 2025-10-22 | 13G/Ano. 1 | Johnson & Johnson Innovation - JJDC, Inc.corporation | 1.8M | 4.9% | 2025-09-30 |
| 2025-09-18 | 13D/Ano. 1 | Dr. James I. Healy ("Healy")individual | 1.9M | 4.2% | 2025-09-11 |
| 2025-09-18 | 13D/Ano. 1 | Dr. Maha Katabi ("Katabi")individual | 1.9M | 4.0% | 2025-09-11 |
| 2025-09-18 | 13D/Ano. 1 | Sofinnova Venture Partners XI, L.P. ("SVP XI")partnership | 1.9M | 4.0% | 2025-09-11 |
| 2025-09-18 | 13D/Ano. 1 | Sofinnova Management XI, L.P. ("SM XI LP")partnership | 1.9M | 4.0% | 2025-09-11 |
| 2025-09-18 | 13D/Ano. 1 | Sofinnova Management XI, L.L.C. ("SM XI LLC")other entity | 1.9M | 4.0% | 2025-09-11 |
13F holders
Tracked managers holding RAPP at their latest 13F. JSON5 of the 30 tracked managers held RAPP at their latest 13F, $21.0M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $9.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 215K | $9.0M | 0.00% | +39K |
| Millennium Management | 2026-06-30 | 155K | $6.5M | 0.00% | -165K |
| Citadel Advisors | 2026-06-30 | 82K | $3.4M | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 26K | $1.1M | 0.00% | +944 |
| Two Sigma Investments | 2026-06-30 | 24K | $1.0M | 0.00% | -4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Rapport Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Rapport Therapeutics (RAPP), SEC CIK 2012593, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-18.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-28.JSON and CSV
- Company record
- EDGAR filing index for CIK 2012593Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of RAPP is sold short?
3,051,500 shares were held short at the 2026-10-15 settlement, 11.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is RAPP's daily short volume?
On 2026-11-02, 229,452 of the 372,156 RAPP shares reported to FINRA were sold short, 61.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does RAPP have fails to deliver?
The SEC's latest file shows 29 RAPP shares failed to deliver at settlement 2026-09-18. Fails are reported per settlement date and published twice a month with a lag.
Are RAPP insiders buying or selling?
Over the last 90 days RAPP insiders reported 11 open-market buys ($22.0M) against 20 sells ($6.9M), so the dollar flow leans toward buying. Latest filing: HEALY JAMES (Director) on 2026-10-28.
Have RAPP insiders filed to sell?
25 Form 144 notices on file for RAPP worth $44.7M at the prices reported; 4 in the last 90 days worth $2.8M. Latest: CHERYL GAULT filed on 2026-09-30 to sell 10,000 shares ($330K) from 2026-09-30.
Who owns 5% or more of RAPP?
7 holders report 5% or more of RAPP in their latest filing, all on Schedule 13G (passive). The largest reported stake is Third Rock Ventures V, L.P. at 13.1% of the class (6,280,525 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own RAPP?
5 of the 30 tracked 13F managers held RAPP shares at their latest filing, $21.0M in all. The largest: D. E. Shaw & Co. (215K shares, $9.0M), Izzy Englander's Millennium Management (155K shares, $6.5M), Ken Griffin's Citadel Advisors (82K shares, $3.4M), Cliff Asness's AQR Capital Management (26K shares, $1.1M), Two Sigma Investments (24K shares, $1.0M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.